Multiple Myeloma Market Expected to Reach US$ 34.58 Billion by 2032 as Advanced Immunotherapies Transform Cancer Treatment

DataM Intelligence has released a new research report titled "Multiple Myeloma Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Multiple Myeloma Market.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/multiple-myeloma-market?ram

The Global Multiple Myeloma Market reached US$ 22.3 billion in 2024 and is expected to reach US$ 34.58 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2025-2032.

The market is witnessing significant growth due to the increasing prevalence of hematological malignancies, rising geriatric population, and growing adoption of targeted therapies and immunotherapies for multiple myeloma treatment. Advancements in diagnostic technologies, improved patient awareness, and expanding access to novel therapeutics are further supporting market expansion across developed and emerging healthcare markets.

Industry participants are increasingly focusing on next-generation monoclonal antibodies, CAR-T cell therapies, and combination treatment approaches to improve patient outcomes and extend remission periods. Strategic collaborations, continuous clinical research activities, and regulatory approvals for innovative treatment options are expected to create strong growth opportunities for pharmaceutical and biotechnology companies operating in the market.

Key Industry Developments

United States:
✅ April 2026: Eli Lilly and Company announced the acquisition of Kelonia Therapeutics to strengthen its in vivo CAR-T platform for multiple myeloma treatment innovation. The deal highlighted KLN-1010, an investigational BCMA-targeted therapy designed to engineer immune cells directly inside the patient's body, representing a major technological advancement in cell therapy for relapsed multiple myeloma.

✅ March 2026: Johnson & Johnson received U.S. FDA approval for TECVAYLI plus DARZALEX FASPRO for relapsed or refractory multiple myeloma. The approval was granted under the FDA's rapid National Priority Voucher Program after the combination demonstrated an 83% reduction in disease progression or death in Phase 3 clinical trials.

✅ January 2026: Janssen Biotech secured FDA approval for DARZALEX FASPRO combined with VRd therapy for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval expanded frontline treatment options and reinforced the growing adoption of subcutaneous antibody-based regimens for improving patient convenience and treatment efficiency.

Japan:
✅ January 2026: GlaxoSmithKline reported positive Japanese patient data from the DREAMM-8 trial evaluating belantamab mafodotin combinations for relapsed or refractory multiple myeloma. The study demonstrated superior treatment responses with manageable safety outcomes, supporting advanced antibody-drug conjugate therapies for Japanese multiple myeloma patients.

✅ December 2025: Sanofi advanced development of subcutaneous Sarclisa therapy platforms for relapsed multiple myeloma, emphasizing improved administration convenience and clinical efficacy. Clinical findings from the IZALCO Phase 2 study highlighted the effectiveness of on-body injector technology combined with carfilzomib and dexamethasone in relapsed patients.

✅ October 2025: GlaxoSmithKline expanded commercialization activities in Japan for BLENREP combination therapies targeting relapsed or refractory multiple myeloma. The company focused on antibody-drug conjugate innovation and broader regional access following encouraging efficacy outcomes from global and Japanese clinical studies.

Strategic Acquisitions & Partnerships
✅ Gilead Sciences - Acquisition
(February, 2026)
Gilead Sciences announced the acquisition of Arcellx in a deal valued at up to $7.8 billion to strengthen its oncology and cell therapy portfolio. The transaction expands Gilead's presence in the multiple myeloma market through anito-cel, a CAR-T therapy already being jointly developed with Kite Pharma for relapsed or refractory multiple myeloma.

✅ Eli Lilly and Company - Acquisition
(April, 2026)
Eli Lilly agreed to acquire Kelonia Therapeutics for up to $7 billion as part of its broader oncology expansion strategy. Kelonia's pipeline includes KLN-1010, an in vivo CAR-T therapy being evaluated for multiple myeloma, aimed at simplifying and improving next-generation cell therapy delivery.

Key Players:
Amgen Inc. | Sanofi | Novartis AG | Teva Pharmaceutical Industries Ltd. | Johnson & Johnson Services, Inc. | Bristol-Myers Squibb Company | ONO PHARMACEUTICAL CO., LTD. | Pfizer Inc. | Karyopharm | Amneal Pharmaceuticals LLC

Key Highlights: Top 5 Key Players in Multiple Myeloma Market 2026
-Johnson & Johnson Services, Inc.: Advanced the multiple myeloma treatment landscape through the expansion of Tecvayli (teclistamab) and DARZALEX (daratumumab) combination therapies, demonstrating strong progression-free survival benefits in relapsed/refractory multiple myeloma patients. The company also strengthened its BCMA-targeted immunotherapy portfolio with continued global expansion of CARVYKTI cell therapy programs.

-Bristol-Myers Squibb Company: Expanded its hematology innovation pipeline through continued development of Abecma (idecabtagene vicleucel) CAR-T therapy and next-generation CELMoD candidate iberdomide. Recent clinical updates highlighted durable MRD negativity and improved long-term response rates in newly diagnosed and relapsed multiple myeloma patients.

-Pfizer Inc.: Strengthened its presence in BCMA-targeted therapy with ELREXFIO (elranatamab), which achieved positive Phase III trial outcomes showing clinically meaningful progression-free survival improvement in relapsed/refractory multiple myeloma. Pfizer also continued expanding global regulatory approvals and commercialization activities for its bispecific antibody platform.

-Sanofi: Enhanced its hematology portfolio with the broader adoption of Sarclisa (isatuximab) in combination regimens for relapsed multiple myeloma. The company focused on expanding frontline and transplant-ineligible treatment settings through ongoing clinical trials evaluating combination efficacy and deeper remission outcomes in multiple myeloma care.

-Karyopharm Therapeutics Inc.: Continued advancing XPOVIO (selinexor)-based regimens for relapsed/refractory multiple myeloma while presenting new clinical findings supporting improved therapeutic response durability. The company also expanded research into combination therapies designed to overcome treatment resistance in heavily pretreated patients.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/multiple-myeloma-market?ram

Main Drivers and Trends Shaping the Future of the Multiple Myeloma Market
-Rising Disease Burden: Increasing incidence of hematologic cancers, aging populations, and improved diagnostic awareness are driving higher demand for advanced multiple myeloma therapies worldwide.

-Advancement in Immunotherapy: Rapid adoption of CAR-T cell therapies, bispecific antibodies, and monoclonal antibodies is transforming treatment outcomes by improving survival rates and reducing relapse risks.

-Personalized Medicine Growth: Precision oncology, biomarker-based treatment selection, and genomic profiling are enabling tailored therapeutic strategies and more effective disease management.

-Expansion of Combination Therapies: Pharmaceutical companies are focusing on multi-drug regimens integrating proteasome inhibitors, immunomodulatory drugs, and corticosteroids to enhance treatment efficacy.

-Strong R&D Investments: Increased clinical trials, regulatory approvals, and collaborations between biotechnology firms and research institutions are accelerating innovation in next-generation therapies.

-Market Challenges: High treatment costs, therapy-related adverse effects, limited accessibility in developing regions, and complex reimbursement frameworks continue to restrain broader market adoption.

Regional Insights:
-North America: 58.28% (Largest share, driven by strong adoption of advanced therapeutics, high healthcare spending, and increasing diagnosis rates across the U.S. and Canada).

-Europe: 20.65% (Supported by favorable reimbursement policies, rising use of immunotherapies, and strong presence of leading pharmaceutical companies).

-Asia Pacific: 16.57% (Fastest-growing region, fueled by expanding patient population, improving healthcare infrastructure, and rising approvals of novel therapies in China, Japan, and India).

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=multiple-myeloma-market?ram

Market Segmentation Analysis:
-By Type: Immunoglobulin G (IgG) Myeloma Dominates Due to High Incidence
Immunoglobulin G (IgG) myeloma represents the most common type, driven by its high prevalence among diagnosed multiple myeloma patients and frequent detection during routine blood investigations.
Immunoglobulin A (IgA) myeloma follows, associated with aggressive disease progression and increased monitoring requirements in hematology care.
Light chain myeloma and rare variants such as non-secretory myeloma account for a smaller share, gaining clinical attention due to diagnostic complexity and the need for advanced biomarker testing.

-By Treatment: Targeted Therapy Leads with Expanding Adoption
Targeted therapy dominates the market, supported by the growing use of proteasome inhibitors, monoclonal antibodies, and immunomodulatory drugs in frontline and relapsed treatment settings.
Stem cell transplantation remains a key treatment option for eligible patients, especially younger individuals requiring long-term disease control.
Chemotherapy, radiation therapy, and emerging CAR-T cell therapies continue expanding, driven by advancements in precision oncology and personalized treatment approaches.

-By End-User: Hospitals Lead Owing to Advanced Oncology Care
Hospitals dominate the end-user segment due to access to specialized oncology departments, stem cell transplant facilities, and comprehensive diagnostic infrastructure.
Specialty cancer clinics are witnessing strong growth as patients increasingly seek personalized hematology and immunotherapy services.
Research institutes and ambulatory care centers also contribute steadily, supported by rising clinical trials and outpatient-based multiple myeloma treatment programs.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.